1
Anti-Pseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in
2
Murine Lung
3
Rishi Pabary1,2, Charanjit Singh1, Sandra Morales3, Andrew Bush1,2, Khalid Alshafi4, Diana Bilton4,
4
Eric WFW Alton1, Anthony Smithyman3 and Jane C. Davies1,2#
5
1National
6
2Department
7
3Special
8
4Department
9
5Adult
Heart and Lung Institute, Imperial College London
of Paediatric Respiratory Medicine, Royal Brompton Hospital, London
Phage Services, Australia
of Microbiology, Royal Brompton Hospital, London
Cystic Fibrosis Unit, Royal Brompton Hospital, London
10
11
Running Head: Phage reduces murine infection and inflammation
12
Corresponding Author: Professor Jane C. Davies (j.c.davies@imperial.ac.uk)
13
Keywords (MESH terms): Bacteriophages, bronchoalveolar lavage, cystic fibrosis, drug
resistance (microbial), infection, inflammation
14
15
16
1
17
Abstract
18
Rationale: As antibiotic resistance increases, there is a need for new therapies to treat
19
infection, particularly in cystic fibrosis (CF) where Pseudomonas aeruginosa (Pa) is a ubiquitous
20
pathogen associated with increased morbidity and mortality. Bacteriophages are an attractive
21
alternative treatment as they are specific to the target bacteria and have no documented side-
22
effects.
23
Methods: Efficacy of phage cocktails was established in vitro. Two Pa strains were taken
24
forward into an acute murine infection model with bacteriophage administered either
25
prophylactically, simultaneously or post-infection. Assessment of infective burden and
26
inflammation in bronchoalveolar lavage fluid (BALF) was undertaken at various times.
27
Results: With low infective doses, both control mice and those undergoing simultaneous phage
28
treatment cleared Pa infection at 48hrs but there were fewer neutrophils in BALF of phage-
29
treated mice (median [range] 73.2 [35.2-102.1], x104/ml vs. 174 [112.1-266.8] p < 0.01 for
30
clinical strain; median [range] 122.1 [105.4-187.4] x104/ml vs. 206 [160.1-331.6], p < 0.01 for
31
PAO1). With higher infective doses of PAO1, all phage-treated mice cleared infection at 24hrs
32
whereas infection persisted in all control mice; median [range] CFU/ml 1305 [190-4700], p <
33
0.01. Bacteriophage also reduced CFU/ml in BALF when administered post-infection (24 hours)
34
and both CFU/ml and inflammatory cells in BALF when administered prophylactically. Reduction
35
in soluble inflammatory cytokines in BALF was also demonstrated under different conditions.
2
36
Conclusion: Bacteriophages are efficacious in reducing both bacterial load and inflammation in
37
a murine model of Pa lung infection. This study provides proof-of-concept for future clinical
38
trials in patients with CF.
39
3
40
Introduction
41
Antimicrobial resistance in general has been flagged as a major global health risk by the World
42
Health Organisation (1), with the rising incidence of multi-drug resistant gram negative
43
bacteria, such as Pseudomonas aeruginosa, of particular concern.. Pseudomonas aeruginosa
44
(Pa) is a ubiquitous, gram-negative bacterium that opportunistically infects patients with
45
chronic suppurative lung diseases such as cystic fibrosis (CF), and is clearly associated with
46
increased morbidity and mortality (2). Antimicrobial therapy is usually effective at eradicating
47
initial infection (3) but most patients ultimately become chronically infected as Pa is both
48
inherently resistant to many classes of antibiotics due to its efflux-pump system (4) and rapidly
49
develops mutation-based resistances in the presence of exposure to antimicrobial agents (5).
50
Bacterial infection is closely associated with pulmonary inflammation in CF and, although there
51
is increasing evidence that this paradigm may be simplistic (6), it is clear that neutrophilic
52
inflammation causes lung injury (7) and declines following antibiotic treatment of Pa in CF (8).
53
For CF patients, failure of conventional antibiotics facilitates the development of chronic Pa
54
infection whereby originally free-floating (planktonic) organisms switch to a biofilm mode of
55
growth (9). In addition to increasing antibiotic resistance (10), there are significant side-effects
56
associated with conventional antimicrobials, particularly when they are used repeatedly or over
57
long periods of time. These include renal and oto-toxicity, both of which are commonly
58
encountered in adult clinics. There is thus an urgent need for novel anti-pseudomonal therapies
59
for patients with CF.
4
60
Bacteriophages are naturally occurring viruses that specifically target bacterial cells (11). First
61
described by Felix d’Herelle in 1917 (12), they were the focus of several therapeutic studies in
62
the 1920s. However, these were run under conditions not comparable to modern standards
63
and lacked suitable controls and due to the low quality of some products, results were often
64
inconsistent (13). Coupled with the discovery of antibiotics in 1928 (14), this meant that
65
widespread clinical use was mainly limited to Eastern Europe (12, 15).
66
Bacteriophages offer several advantages over conventional antibiotics: they are highly selective
67
so can be targeted against pathogenic bacteria without disturbing the resident bacterial flora;
68
they multiply exponentially in the presence of host (bacterial) cells rather than decreasing in
69
concentration over time, thereby potentially providing treatment targeted to the sites of need
70
(12); they can adapt and mutate like bacteria, thereby potentially reducing the emergence of
71
resistant bacterial strains (16, 17) and they appear to be relatively free of side-effects (17).
72
Bacteriophages are widely used in food preservation, being applied for example to the surfaces
73
of preserved meats and cheeses (18, 19). Bacteriophage have been shown to be efficacious in
74
vitro against Pa in biofilms (20) and in vivo in murine models of Pa septicaemia: between 50-
75
100% of mice infected with a lethal intraperitoneal dose of Pa survived when administered a
76
single dose of intravenous (21) or intraperitoneal (22) phage up to one hour post-infection.
77
Recent studies of acute lung infection in mice have used bioluminescent strains of Pa to
78
demonstrate phage efficacy; bioluminescence decreased following administration of phage
79
with an associated reduction in bacteria recovered from bronchoalveolar lavage fluid (BALF)
80
and disease severity (as assessed by histological analysis of lung tissue) in phage-treated mice
81
compared with controls (23, 24). However, none of these studies investigated the impact of
5
82
phage-targeted pseudomonal killing on lung inflammation. This is highly relevant as persistent
83
neutrophilic inflammation has been associated with lung injury (25) and, even during periods of
84
stability, CF patients with chronic Pa infection have higher inflammatory indices than subjects
85
without CF (26). Reduction in bacterial load demonstrated in previous studies does not
86
necessarily equate to attenuation of inflammatory damage. An important unanswered question
87
remains as to whether phage therapy itself induces a host inflammatory response either
88
directly or secondary to phage-induced Pa lysis (leading to release of toxins such as LPS) or
89
reduces the response by hastening bacterial clearance.
90
Although in vitro models suggest that bacteriophages can be deposited successfully in the
91
human lung by nebulisation (27), no studies of efficacy in lung infection have been undertaken
92
to date under strict regulatory criteria. However, a small randomised controlled trial in the
93
United Kingdom reported that a single topical dose of phage reduced symptoms in patients
94
with persistent Pa ear infections refractory to multiple courses of antibiotics, with no reported
95
adverse events (28). Safety has also previously been reported in children receiving intravenous
96
phage (29).
97
Based on the previously published data, we consider that bacteriophages could be a useful
98
treatment for Pa in patients with CF. We hypothesised that such treatment would reduce
99
bacterial load as previously described but also thereby reduce inflammation and the
100
detrimental downstream consequences thereof. In this study, we test specifically-designed
101
anti-Pa bacteriophage cocktails in a murine model of Pa lung infection. Pa strains assessed as
102
being susceptible to bacteriophage cocktails in vitro were studied in vivo in order to determine
6
103
if there were any immunological benefits of phage therapy. We assess the effect on lung
104
bacterial load, systemic spread of infection and pulmonary inflammation and explore the
105
potential both for treatment of infection and for prophylaxis.
106
Materials and Methods
107
Ethics Statement
108
Female BALB/c mice (Harlan, UK) were housed in a specialised animal facility in accordance
109
with European regulations. Food and drink were provided ad libitum. The work was
110
prospectively approved by the United Kingdom Home Office and National Ethics Committee.
111
Bacteriophage isolation and cocktail selection
112
Bacteriophages for this study were isolated by Special Phage Services Pty Ltd (Sydney, Australia)
113
from a variety of environmental sources in New South Wales, Australia, using different
114
protocols as previously described. (30) Three different bacteriophage cocktails: cocktail 1 (Pa
115
24, Pa 25 and Pa 37), cocktail 2 (Pa 39, Pa 67, Pa 77 and Pa 119) and cocktail 3 (Pa 3, Pa 6, Pa
116
10, Pa 32 and Pa 37) were selected based on their abilities to delay or inhibit appearance of
117
putative phage-resistant cells in liquid or solid media. Each bacteriophage was tested for its
118
morphology and host spectrum of activity against PAO1 and ten P. aeruginosa clinical isolates
119
collected in Australia (Table 1 Supplementary Information). The approximate molecular weight
120
(MW) for each phage was also determined by pulsed-field electrophoresis (31) and each phage
121
shown to be different by restriction digest (data not shown).
122
7
123
In vitro Phage Susceptibility Testing
124
Before use in vivo, susceptibility of our chosen bacterial isolates to the bacteriophage cocktails
125
was initially confirmed using conventional plaque assays (32)). PAO1, a well-described
126
laboratory reference strain (33, 34), and five Pa strains isolated from the sputa of adult in-
127
patients with CF at the Royal Brompton Hospital, London, were tested against the three novel
128
bacteriophage cocktails. Pure isolates were inoculated into 10mls tryptone soy broth (TSB:
129
Oxoid, UK) and cultured overnight at 37oC with agitation. Optical density (OD) of the broths was
130
measured spectrophotometrically (Spectronic, UK) and adjusted to 0.1 (equivalent to
131
approximately 1x108 colony forming units (CFU)/ml) by dilution with sterile TSB. 100µl of the
132
diluted broth was added to 3mls semi-solid agar (prepared by dissolving 3g of TSB powder
133
(Sigma, UK) and 0.4g agar (Sigma, UK) in 100mls deionised water and autoclaving) that had
134
been maintained at 55oC in a water bath before pouring onto Pseudomonas-specific agar (PSA:
135
Oxoid, UK). After cooling, 10µl aliquots of each bacteriophage cocktail (6.2 x 1010 plaque-
136
forming units (PFU)/ml at neat and serially log10 diluted down to 10-6) were pipetted onto the
137
prepared bacterial lawns and incubated overnight at 37oC. The cocktail that was most broadly
138
efficacious with lab strain PAO1 and the most susceptible strain isolated from CF patients
139
(henceforth termed “clinical strain”) were taken forward for these proof-of-principle in vivo
140
studies.
141
In vivo Methodology
142
Following overnight culture of the two selected bacterial strains in TSB, broth was centrifuged
143
(Meadowrose Scientific, UK) at 2000g at 4oC for ten minutes and the resultant cell pellet
8
144
resuspended in 10mls of phosphate buffered saline (PBS: Gibco, UK). OD was adjusted by
145
dilution with PBS; the relationship between CFU/ ml and OD was previously determined by
146
serial dilution and colony counting as per Miles and Misra (35).
147
Adult BALB/C mice were anaesthetised by isoflurane inhalational. In a pilot, dose-finding study,
148
n=3/ group received 50µl by nasal gavage (sniffing) of 1x109, 5x108,1x108 or 5x107 CFU/ml. Mice
149
in the first 3 groups were either deceased or unwell 24hrs post-infection. A maximum inoculum
150
of 5x107 CFU/ml was therefore selected for initial experimental use
151
Mice were infected by intranasal sniffing initially with 50l of 5x107 CFU/ml (2.5 x 106 CFU; ‘low
152
dose’); in later experiments where bronchoalveolar lavage (BAL) was carried out 24hrs post-
153
infection, we were able to apply 50l of 5x108 CFU/ml (2.5 x 107 CFU; ‘high dose’). 20l (1.2x109
154
PFU) intranasal phage therapy or buffer (controls) was administered either simultaneously,
155
24hrs post-infection or 48hrs pre-infection. BAL was carried out either 24 or 48hrs post-
156
infection using the following technique: terminal general anaesthesia was achieved by
157
intraperitoneal administration of Hypnorm (Vetapharma, UK) and Hypnovel (Roche, UK). After
158
cessation of circulation, the trachea was surgically exposed and cannulated with a 22g
159
AbbocathTM (Hospira, UK). Bronchoalveolar lavage (BAL) was performed with 500l PBS
160
instillation and aspirated three times. Spleens were dissected and harvested into 500l PBS.
161
Processing of Samples
162
100l BAL was serially log10 diluted and 5 x 10l drops cultured overnight at 37oC on PSA plates
163
as per Miles and Misra (35). Non-quantitative culture on PSA agar was also performed on
164
homogenised explanted spleens to determine systemic spread.
9
165
Remaining BAL was centrifuged at 4oc, 2000g for ten minutes. 100l aliquots of supernatant
166
were stored at -80oC for subsequent batched analysis of inflammatory cytokines. Cytokines
167
were selected based on their inclusion in a commercially available multiplex ELISA platform
168
(MesoScale Discovery (MSD) mouse pro-inflammatory 7-plex ultra-sensitive assay). The
169
remaining cell pellet was resuspended in 200l PBS. 20l of this solution was added to 40l
170
tryphan blue (Sigma, UK) and 20l PBS (1 in 4 dilution) and total inflammatory cells counted
171
with Neubauer haemocytometer. A further 100ul was used for differential cell count following
172
cytospin (Shandon, UK) for five minutes at 400rpm. Slides were fixed with methanol and
173
stained using May-Grunwald-Giesma Quickstain kit prior to mounting with DPX (Sigma, UK). 300
174
cells per slide were counted by one investigator following blinding of the slides by a second
175
investigator; unblinding took place at the end of each part of the study.
176
Statistical Analyses
177
Based on modest group sizes and assuming non-Gaussian data distribution, Mann-Whitney t-
178
test was performed on all datasets using Prism 6.0 (GraphPad, United States). Eight mice was
179
the arbitrary number decided upon for each arm of each condition being tested; if clear
180
differences became apparent with fewer (minimum of six mice in each arm), the study was
181
stopped in accordance with ethical standards of animal research. Median data and range are
182
presented. The null hypothesis was rejected if p<0.05.
183
10
184
Results
185
Lytic activity of bacteriophage cocktail in vitro
186
All three bacteriophage cocktails were effective against PAO1 at phage dilutions from neat to
187
10-5. This result matched expectations given the reported activity of the individual phages
188
against this strain (Table 1 Online Supplement). When tested against the clinical isolates,
189
bacteriophage cocktail 1 was active against the 5 clinical isolates/strains tested whilst
190
bacteriophage cocktail 2 and 3 infected only 3 out of the 5 isolates/strains. Sensitivities of each
191
clinical strain tested to each phage cocktail are shown in Table 1:
192
The broad-spectrum of activity of a bacteriophage cocktail has been suggested as an important
193
characteristic to overcome the limitations of specificity associated with bacteriophages. Based
194
on the susceptibility results obtained, bacteriophage cocktail 1 was selected for in vivo use.
195
Similarly, as there are reports suggesting good correlation between in vitro activity and in vivo
196
phage efficacy (36), the isolate/strain PA12B-4973 was selected for in vivo experimentation as
197
the phage cocktail 1 was very efficient against this isolate/strain even at a very low
198
concentration (10-6).
199
Simultaneous Administration of Bacteriophage and Pa
200
Two experimental conditions were tested. Initially, mice were infected with 2.5 x 106 bacteria
201
(50 l of 5x107 CFU/ml) PAO1 (n=16) or the clinical strain (n=12) and immediately afterwards,
202
whilst under the same inhalational anaesthetic, 20l phage (n=14) or buffer (n=14) was
203
administered. Samples were harvested at 48hrs. BALF culture demonstrated that all phage-
11
204
treated mice and most control mice cleared Pseudomonas; 2/6 control mice infected with the
205
clinical strain had persistent infection but with low bacterial load (20 and 40 CFU/ml) on
206
quantitative culture. Systemic spread, as indicated by positive splenic cultures, was not seen in
207
either group. However, inflammation was significantly reduced in the phage-treated animals.
208
Total inflammatory cells (predominantly neutrophils) were lower with both bacterial strains
209
(Table 2 in Supplemental Information Section and Figure 1) as were several cytokines although
210
this was only observed with the clinical strain (Tables 3a and 3b in Supplemental Information
211
Section and Figure 2).
212
These data provided evidence for a phage effect, but the ability of control animals to clear this
213
dose of Pa meant that no signal on bacterial killing could be demonstrated. Therefore, we next
214
infected mice with a higher dose of PAO1 (2.5x107 CFU/ml) and chose an earlier, 24hr, time
215
point for sampling. Mice infected with higher inoculums of the clinical strain became terminally
216
unwell in less than 24hrs and thus only PAO1 was used for ongoing work. Under these
217
conditions, all control mice had detectable Pa infection (median [range] 1305 [190-4700]
218
CFU/ml). In contrast, no bacteria were cultured from BAL from any phage treated mice (Figure
219
3a; p <0.01). There was no growth from splenic cultures in either group. IL-10 (p < 0.01) and IL-
220
1 (p < 0.05) were significantly reduced in phage-treated mice compared with controls (Figure
221
3b) but there was no difference in the five other cytokines measured or in inflammatory cell
222
counts (Tables 4 and 5 in Supplemental Information Section). Having demonstrated efficacy
223
with simultaneous administration, and recognising how poorly this mirrored any clinical
224
context, we went on to assess delayed and prophylactic phage administration.
12
225
Delayed Administration of Bacteriophage
226
High dose (2.5x107 CFU/ml) PAO1 was inoculated intranasally and bacteriophage or buffer
227
administered 24hrs hours later. Samples were obtained a further 24hrs after this. In contrast to
228
control mice, who all had positive BAL cultures (5950 [40 – 194000] CFU/ml), complete
229
clearance was seen in 6/7 (86%) of phage treated mice (and median CFU/ml was significantly
230
lower (0 [0-160] CFU/ml, p < 0.01, Figure 4a). Two control mice had growth of Pa from splenic
231
culture, indicating systemic spread of infection. This was not seen in any of the phage-treated
232
animals. There was a reduction in IL-10 (p < 0.05) and KC (keratinocyte chemoattractant) (p <
233
0.01) in phage-treated mice (Figure 4b) but no reduction in other inflammatory cytokines or in
234
cell counts (Tables 6 and 7 in Supplemental Information Section).
235
‘Prophylactic’ Administration of Bacteriophage
236
Bacteriophage or buffer was instilled 48hrs prior to intranasal infection with high dose (2.5x10 7
237
CFU/ml) PAO1. Samples were obtained 24 hours after bacterial infection. Two control mice died
238
in this 24 hour period. Of those surviving, all had persistent and high levels of bacteria in BAL
239
(1.8 x 106 [1140 – 1.64x1010] CFU/ml). In contrast, 5/7 (71%) of phage pre-treated mice had
240
successfully cleared the infection and those which had not, had only low levels of bacteria
241
detected (0 [0-20] CFU/ml, p < 0.01, Figure 5a). Four of five (80%) surviving control mice had
242
positive splenic cultures indicating systemic spread. This was not seen in any of the phage-
243
treated mice (n=7).
244
KC (Figure 5b) (p <0.01) and total and differential cell counts (Figure 6) in BALF of mice pre-
245
treated with phage were significantly reduced compared with controls (Table 8 in
13
246
Supplementary Information Section and Figure 6) although there was no difference in other
247
cytokines (Table 8 in Supplementary Information Section).
248
Discussion
249
We have shown that delivery of selected bacteriophage cocktails during, before or after lung
250
infection with Pa has a significant impact on local bacterial burden, systemic spread of infection
251
and lung inflammatory responses.
252
We first confirmed the expected activity of three bacteriophage cocktails in vitro against the
253
laboratory strain, PAO1, and demonstrated the activity of the three cocktails against some but
254
not all of clinical isolates of Pa taken from patients with CF. The ability of a phage to form
255
plaques on a lawn of the target bacteria is seen as the basic requirement for phage therapy.
256
Furthermore, correlation between bacteriophage activity in vitro and subsequent success in
257
vivo has been reported before (36). This study supports the importance of this correlation,
258
although care should be taken not to assume this is the only property required for efficacy (37).
259
Subsequently, bacteriophage reduced infective burden and inflammatory response in a murine
260
infection model when using an initial theoretical multiplicity of infection (MOI) of ~100. At
261
lower bacterial doses, no difference in infective burden was demonstrated, as mice were
262
capable of spontaneous clearance, but there was a significant reduction in neutrophils. At
263
higher infective doses, the objective of achieving persistent infection was achieved, but only in
264
control mice; all phage-treated mice retained the ability to clear their lungs of infection.
265
Similarly, in experiments where phage or buffer was administered post-infection, there were
266
significantly lower CFU/ml in BALF of phage-treated mice compared with controls, although no
14
267
difference was seen in inflammatory cells. Finally, the efficacy of prophylactic phage was also
268
demonstrated; all treated mice survived a high dose of inoculum and had significantly lower
269
CFU/ml and neutrophils in BALF compared to controls.
270
In keeping with the observation that BALB/c mice are inherently resistance to Pa infection (38),
271
most mice in this study were able to clear a low dose of intranasally administered Pa with no
272
evidence of systemic spread even in the absence of phage treatment. However, such mice
273
demonstrated neutrophilic inflammation at 48 hours in response to both strains of Pa
274
administered. This inflammatory response was significantly reduced when bacteriophage were
275
administered simultaneously. This is significant because, although inflammation and infection
276
may be dissociated in CF (39, 40), the role of neutrophils in mediating tissue injury is clear and
277
therefore treatments that reduce their number may be of benefit (41). However, as trials of
278
leukotriene B4 receptor antagonists demonstrate, this paradigm may be over-simplistic (42)
279
In addition, reduced levels of BALF IL-10, IL-6, TNF- and IL-12p70 were demonstrated in
280
phage-treated mice infected with the clinical strain of Pa, with a trend towards reduced KC.TNF-
281
 plays a key role in the acute phase response, promoting recruitment of neutrophils to sites of
282
infection (43, 44) and is also one of the physiological stimuli for IL-6 production, along with
283
bacterial endotoxin (45) . IL-12p70 is the biologically active form of IL-12 which is important in
284
Th1 immune responses to bacteria and viruses (46) whilst KC is a major neutrophil
285
chemoattractant (47). The reduction in neutrophil count and cytokine levels in BALF of phage-
286
treated mice 48hrs following infection with a clinical Pa strain suggests that bacteriophage
287
complements the inherent resistance of these mice to Pa, hastening clearance and thereby
15
288
diminishing the inflammatory response. That there was no significant reduction in cytokine
289
levels in phage-treated mice infected with PAO1 most likely reflects a difference in virulence
290
between the two strains of bacteria as differences did become apparent when the inoculum of
291
PAO1 was increased.
292
When numbers of nasally instilled PAO1 were increased ten-fold and BAL was performed
293
earlier at 24hrs, control mice had significant numbers of Pa present in the BALF, whereas all
294
phage-treated mice had completely cleared the infection. Lower levels of inflammation (IL-1
295
and IL-10 and a trend in IL-6) were also observed.
296
In addition to the co-administration experiments, we demonstrated efficacy when phage were
297
administered either after bacterial infection, mimicking a clinical ‘treatment’ scenario or
298
beforehand, as ‘prophylaxis’. Both resulted in a significant impact on bacterial load and
299
inflammatory response and suggest potential clinical utility. The prophylaxis experiments also
300
indicate that phage is relatively stable in the murine lung (for at least 24hrs). This raises a
301
concern that carryover phage might be present when plating BAL from infected animals, which
302
has the potential to reduce CFU counts ex vivo. The way in which samples were processed
303
aimed to minimise the risk of phage-bacteria interactions in vitro but it was not possible to
304
demonstrate that no carryover phage was present in cultured BALF. This question has been
305
addressed previously; studies using bioluminescent strains to monitor phage efficacy in real
306
time (23, 48) demonstrate that phage activity clearly occurs in the lungs and is not the result of
307
ex vivo culturing only. This issue is analogous to culturing BALF or sputum from patients already
308
on antibiotics. The fact that bacteria do not grow in vitro leads to the conclusion that infection
16
309
is not present; it is not possible to be sure if this is because of efficacy in vivo or an in vitro
310
effect after samples are collected. Molecular assay testing to address this issue may be applied
311
to future experimental models.
312
What we have not done in this set of experiments is model chronic infection with mucoid or
313
biofilm modes of growth. Transgenic CF mice in general do not recapitulate the lung disease
314
characteristic of human CF, and most investigators have resorted to the use of artificial means
315
of establishing chronic infection such as agar beads. Whilst potentially useful for studying host
316
responses, we decided against this model for the testing of a topically applied therapeutic,
317
penetration of which may have been adversely affected by the presence of the agar. We may,
318
in the future be able to study such mechanisms in alternative animal models such as the β-ENaC
319
over-expressing mouse or the CF pig or ferret. Data from other fields suggesting that
320
bacteriophage are effective against biofilm-growing organisms (20, 49-51) provide encouraging
321
support for this approach.
322
Whilst all mice infected with Pa and simultaneously treated with bacteriophage cleared
323
infection (Figure 3a), colonies remained present in BALF of some mice who received delayed or
324
prophylactic dosing of phage (Figures 4a and 5a) albeit in far lower quantities than untreated
325
mice. This is most likely indicative of incomplete clearance due to higher bacterial load in mice
326
where phage treatment was delayed and/or because BAL was performed at an earlier time
327
point (24hrs rather than 48hrs) but the possibility that the recovered Pa had evolved phage-
328
resistance cannot be discounted. The recovered colonies were not retested in vitro for phage
17
329
susceptibility but this will be done in future experiments as the question of whether sensitive
330
bacterial strains become resistant to bacteriophage over time is key to clinical application.
331
Although the majority of the data supports a reduction and benefit in the general
332
inflammatory response when bacteriophages are used, different conditions led to variable
333
changed in specific soluble inflammatory markers. Five cytokines were lower in phage-treated
334
mice infected with clinical Pa whereas no phage-related differences were seen with PAO1 at
335
the same inoculum; given the severity of illness noted in mice infected with higher doses of the
336
clinical strain, this could be attributed to differences in virulence of the Pa strains. At higher
337
inoculums of PAO1, IL-10 and IL-1b were lower in phage-treated animals following
338
simultaneous administration, IL-10 and KC were lower when phage was given 24hrs post-
339
infection and only KC was lower with prophylactic phage administration. Difficulties in
340
standardisation of animals, exacerbating inherent biological variability under each condition,
341
may have contributed to this; although all mice were adult female BALB/C, exact age and
342
weight could not be matched which may have affected response. There may also have been
343
underpowering for some of these effects due to our attempts to limit animal numbers used in
344
the experiments.
345
Reduction in IL-10 in phage-treated animals was seen across several conditions tested. This
346
initially seemed counter-intuitive as IL-10 inhibits production of pro-inflammatory cytokines
347
(including IL-1, IL-6, IL-12 and TNF-) by T-cells, thereby down-regulating the acute immune
348
response (52); there was close correlation of IL-10 with IL-1, IL-6 and TNF- (r2 0.734 – 0.787)
349
but not with IL-12p70 (r2 = 0.368) in this study. However, recent evidence suggests that IL-10
18
350
response is related to the severity of a preceding pro-inflammatory response (52), which is
351
subsequently down-regulated by IL-10 to prevent ongoing inflammation; hence high levels are
352
associated with protracted infection and blockade of IL-10 may in fact promote clearance of
353
bacteria (53). If this is the case, and there remains no consensus in the literature due to the
354
complexity of the IL-10 signalling (52), then reduced IL-1, IL-6 and TNF- in experiments with
355
the clinical strain, reduced IL-1 and a trend towards reduced IL-6 (p = 0.06) when the inoculum
356
of PAO1 was increased with simultaneous dosing of phage and a trend towards reduced IL-1
357
and IL-6 with later dosing of phage, could account for reduced “anti-inflammatory” IL-10 in this
358
study; as there was less initial inflammation in phage-treated mice, less IL-10 was detected.
359
Further support for this theory is the fact that IL-10, of all the measured cytokines in this study,
360
correlated most strongly with absolute neutrophil count across each of the tested conditions (r2
361
= 0.503).
362
From a translational perspective, there were three key findings from this study. Firstly, no
363
evidence of murine toxicity following rapid lysis of Pa by bacteriophage was seen, suggesting
364
that this approach may be safe in a human clinical trial. Secondly, a beneficial effect of phage
365
treatment once infection was established provides support of bacteriophage as a therapy.
366
Thirdly, and perhaps most encouragingly, administration prior to infection is efficacious (both
367
aiding clearance once infection is encountered and reducing neutrophilic inflammation), raising
368
the possibility of prophylaxis, perhaps only at times of increased infection risk, for example
369
during viral infection, which has been linked to acquisition of Pa. UK Registry data (54) currently
370
demonstrates a window of opportunity in childhood and early adolescence, before the majority
371
of patients have become chronically infected with Pa, for such a prophylactic approach. Clearly,
19
372
further work is needed to establish the longevity of phage in the non-bacterial infected host,
373
the frequency with which this would have to be administered and potential host responses
374
(either inflammatory or immune) associated with acute administration or long-term use. It will
375
also be crucial to assess the development of phage-resistance in any persisting bacteria. Recent
376
studies have demonstrated proof-of-concept for prophylactic phage therapy in humans,
377
particularly for gastrointestinal infections (55); regular dosing from a young age of anti-Pa
378
bacteriophage cocktails, selected with knowledge of local strains and sensitivities, is therefore
379
an attractive strategy by which to attempt to reduce the incidence of infection and burden of
380
long-term morbidity and mortality associated with chronic infection.
381
382
20
383
References
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
1.
Organisation WH. Antimicrobial Resistance2013. Available from:
http://www.who.int/mediacentre/factsheets/fs194/en/.
2.
Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and
other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol.
2002;34(2):91-100.
3.
Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in
people with cystic fibrosis. The Cochrane database of systematic reviews. 2009(4):CD004197.
4.
Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and
related organisms. J Mol Microbiol Biotechnol. 2001;3(2):255-64.
5.
Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa:
our worst nightmare? Clinical infectious diseases : an official publication of the Infectious Diseases
Society of America. 2002;34(5):634-40.
6.
Rao S, Grigg J. New insights into pulmonary inflammation in cystic fibrosis. Arch Dis Child.
2006;91(9):786-8.
7.
Downey DG, Bell SC, Elborn JS. Neutrophils in cystic fibrosis. Thorax. 2009;64(1):81-8.
8.
Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF,
Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML. Inflammatory and
microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. American
journal of respiratory and critical care medicine. 2003;168(12):1471-5.
9.
O'Toole GA, Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa
biofilm development. Mol Microbiol. 1998;30(2):295-304.
10.
Nordmann P, Naas T, Fortineau N, Poirel L. Superbugs in the coming new decade; multidrug
resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas
aeruginosa in 2010. Current opinion in microbiology. 2007;10(5):436-40.
11.
Bradbury J. "My enemy's enemy is my friend." Using phages to fight bacteria. Lancet.
2004;363(9409):624-5.
12.
Fruciano DE, Bourne S. Phage as an antimicrobial agent: d'Herelle's heretical theories and their
role in the decline of phage prophylaxis in the West. The Canadian journal of infectious diseases &
medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale /
AMMI Canada. 2007;18(1):19-26.
13.
Lobocka M, Szybalski WT. Advances in Virus Research. Bacteriophages, part A. Preface.
Advances in virus research. 2012;82:xiii-xv.
14.
Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their
use in the isolation of B. influenzae. British Journal of Experimental Pathology. 1929;10(3):226-36.
15.
Kutateladze M, Adamia R. Phage therapy experience at the Eliava Institute. Medecine et
maladies infectieuses. 2008;38(8):426-30.
16.
Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ. Novel alternatives to antibiotics:
bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. Journal of applied
microbiology. 2008;104(1):1-13.
17.
Thiel K. Old dogma, new tricks--21st Century phage therapy. Nature biotechnology.
2004;22(1):31-6.
18.
Sillankorva SM, Oliveira H, Azeredo J. Bacteriophages and their role in food safety. Int J
Microbiol. 2012;2012:863945.
19.
Greer GG. Bacteriophage control of foodborne bacteriat. J Food Prot. 2005;68(5):1102-11.
21
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
20.
Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. Bacteriophage cocktail for the
prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system.
Antimicrobial agents and chemotherapy. 2010;54(1):397-404.
21.
Meitert E, Petrovici M, Sima F, Costache G, Savulian C. Investigation on the therapeutical
efficiency of some adapted bacteriophages in experimental infection with Pseudomonas aeruginosa.
Archives roumaines de pathologie experimentales et de microbiologie. 1987;46(1):17-26.
22.
Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J, Li QQ,
Hu J. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenemresistant Pseudomonas aeruginosa. International journal of molecular medicine. 2006;17(2):309-17.
23.
Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L. Bacteriophages can
treat and prevent Pseudomonas aeruginosa lung infections. The Journal of infectious diseases.
2010;201(7):1096-104.
24.
Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. Pulmonary bacteriophage
therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and
prevention. PloS one. 2011;6(2):e16963.
25.
Craig A, Mai J, Cai S, Jeyaseelan S. Neutrophil recruitment to the lungs during bacterial
pneumonia. Infection and immunity. 2009;77(2):568-75.
26.
Jones AM, Martin L, Bright-Thomas RJ, Dodd ME, McDowell A, Moffitt KL, Elborn
JS, Webb AK. Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas
aeruginosa. Eur Respir J. 2003;22(3):503-6.
27.
Golshahi L, Seed KD, Dennis JJ, Finlay WH. Toward modern inhalational bacteriophage therapy:
nebulization of bacteriophages of Burkholderia cepacia complex. Journal of aerosol medicine and
pulmonary drug delivery. 2008;21(4):351-60.
28.
Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic
bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a
preliminary report of efficacy. Clinical otolaryngology : official journal of ENT-UK ; official journal of
Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery. 2009;34(4):349-57.
29.
Fortuna W, Miedzybrodzki R, Weber-Dabrowska B, Gorski A. Bacteriophage therapy in children:
facts and prospects. Medical science monitor : international medical journal of experimental and clinical
research. 2008;14(8):RA126-32.
30.
Kutter ESA. Bacteriophages: Biology and Applications. 1 ed: CRC Press; December 28 2004. 528
p.
31.
Finney M. Pulsed-field gel electrophoresis. Current protocols in molecular biology / edited by
Frederick M Ausubel Roger Brent, Robert E. Kingston, David D. Moore, J.G. Seidman, John A. Smith,
Kevin Struhl. 2001;Chapter 2:Unit2 5B.
32.
H AM. Bacteriophages. 1st ed. New York: Interscience Publishers Inc; 1959. 592 p.
33.
Holloway BW. Genetic recombination in Pseudomonas aeruginosa. Journal of general
microbiology. 1955;13(3):572-81.
34.
Klockgether J, Munder A, Neugebauer J, Davenport CF, Stanke F, Larbig KD, Heeb
S, Schöck U, Pohl TM, Wiehlmann L, Tümmler B. Genome diversity of Pseudomonas aeruginosa PAO1
laboratory strains. J Bacteriol. 2010;192(4):1113-21.
35.
Miles AA, Misra SS, Irwin JO. The estimation of the bactericidal power of the blood. The Journal
of hygiene. 1938;38(6):732-49.
36.
Henry M, Lavigne R, Debarbieux L. Predicting In Vivo Efficacy of Therapeutic Bacteriophages
Used To Treat Pulmonary Infections. Antimicrobial agents and chemotherapy. 2013;57(12):5961-8.
37.
Bull JJ, Gill JJ. The habits of highly effective phages: population dynamics as a framework for
identifying therapeutic phages. Frontiers in microbiology. 2014;5.
22
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
38.
Morissette C, Skamene E, Gervais F. Endobronchial inflammation following Pseudomonas
aeruginosa infection in resistant and susceptible strains of mice. Infection and immunity.
1995;63(5):1718-24.
39.
Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation
in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995;151(4):1075-82.
40.
Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, et al. Early pulmonary
infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol.
2001;32(5):356-66.
41.
Segel GB, Halterman MW, Lichtman MA. The paradox of the neutrophil's role in tissue injury.
Journal of leukocyte biology. 2011;89(3):359-72.
42.
Konstan MW, Doring G, Heltshe SL, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A,
Hamilton A. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor
antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of cystic
fibrosis : official journal of the European Cystic Fibrosis Society. 2014;13(2):148-55.
43.
van Furth R, van Zwet TL, Buisman AM, van Dissel JT. Anti-tumor necrosis factor antibodies
inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth
of Listeria monocytogenes in various organs. The Journal of infectious diseases. 1994;170(1):234-7.
44.
Staugas RE, Harvey DP, Ferrante A, Nandoskar M, Allison AC. Induction of tumor necrosis factor
(TNF) and interleukin-1 (IL-1) by Pseudomonas aeruginosa and exotoxin A-induced suppression of
lymphoproliferation and TNF, lymphotoxin, gamma interferon, and IL-1 production in human leukocytes.
Infection and immunity. 1992;60(8):3162-8.
45.
Hedges S, Svensson M, Svanborg C. Interleukin-6 response of epithelial cell lines to bacterial
stimulation in vitro. Infection and immunity. 1992;60(4):1295-301.
46.
Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. The biology of IL-12: coordinating innate and
adaptive immune responses. Cytokine & growth factor reviews. 2003;14(5):361-8.
47.
Rovai LE, Herschman HR, Smith JB. The murine neutrophil-chemoattractant chemokines LIX, KC,
and MIP-2 have distinct induction kinetics, tissue distributions, and tissue-specific sensitivities to
glucocorticoid regulation in endotoxemia. Journal of leukocyte biology. 1998;64(4):494-502.
48.
Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F, Coffey
A, Ross RP, Hill C. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the
murine lung and on cystic fibrosis lung airway cells. MBio. 2012;3(2):e00029-12.
49.
Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proceedings of
the National Academy of Sciences of the United States of America. 2007;104(27):11197-202.
50.
Hughes KA, Sutherland IW, Jones MV. Biofilm susceptibility to bacteriophage attack: the role of
phage-borne polysaccharide depolymerase. Microbiology. 1998;144 ( Pt 11):3039-47.
51.
Zhang Y, Hu Z. Combined treatment of Pseudomonas aeruginosa biofilms with bacteriophages
and chlorine. Biotechnology and bioengineering. 2013;110(1):286-95.
52.
Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. Journal of
immunology. 2008;180(9):5771-7.
53.
Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti-inflammatory and pro-inflammatory roles
of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Current opinion in pharmacology.
2009;9(4):447-53.
54.
Registry UC. Annual Data Report 2013. 2014:56.
55.
Sulakvelidze A, Alavidze Z, Morris JG, Jr. Bacteriophage therapy. Antimicrobial agents and
chemotherapy. 2001;45(3):649-59.
521
23
522
24
523
Table
Clinical Isolate
Cocktail 1
Cocktail 2
Cocktail 3
PA 12B-4854
PA 12B-4973
PA 12B-5001
PA 12B-5025
PA 12B-5099
10-2
10-6
10-5
10-2
10-2
No effect
10-4
10-5
10-2
No effect
No effect
10-6
10-6
10-4
No effect
524
525
Table 1: Susceptibility of five clinical strains of Pa to three bacteriophage cocktails. Cocktail 1
526
was more broadly efficacious and PA12B-4973 (from here on known as clinical strain) was most
527
broadly sensitive, and therefore these were used for ongoing work.
528
Figure Legends
529
Figure 1: Differential cell counts (median/range) from BAL performed at 48hrs in mice
530
inoculated with 2.5 x 106 of a clinical strain of Pa and simultaneously treated with 20l
531
bacteriophage cocktail (containing 1.24 x 109 PFU) or SM buffer.
532
Figure 2: Pro-inflammatory cytokines (median/range) from BAL performed at 48hrs in mice
533
inoculated with 2.5 x 106 of a clinical strain of Pa and simultaneously treated with 20l
534
bacteriophage cocktail (containing 1.24 x 109 PFU) or SM buffer.
535
Figure 3a: Colony counts/ml from BAL performed at 24hrs in mice inoculated with 2.5 x 10 7 of
536
PAO1 and simultaneously treated with 20ul bacteriophage cocktail (containing 1.24 x 10 9 PFU)
537
or 20l SM buffer. If no colonies were visible to the naked eye, this is reported as 0 CFU/ml; the
538
theoretical limit of detection was 100 CFU/ml as 10l drops of BALF were cultured.
25
539
Figure 3b: Pro-inflammatory cytokines (median/range) from BAL performed at 24hrs in mice
540
inoculated with 2.5 x 107 of PAO1 and simultaneously treated with 20l bacteriophage cocktail
541
(containing 1.24 x 109 PFU) or SM buffer.
542
Figure 4a: Colony counts/ml from BAL performed at 48hrs in mice inoculated with 2.5 x 107 of
543
PAO1 and treated with 20l bacteriophage cocktail (containing 1.24 x 109 PFU) or SM buffer
544
24hrs after the initial infection. If no colonies were visible to the naked eye, this is reported as 0
545
CFU/ml; the theoretical limit of detection was 100 CFU/ml as 10l drops of BALF were cultured.
546
Figure 4b: Pro-inflammatory cytokines (median/range) from BAL performed at 48hrs in mice
547
inoculated with 2.5 x 107 of PAO1 and treated with 20l bacteriophage cocktail (containing 1.24
548
x 109 PFU) or SM buffer 24hrs after the initial infection.
549
Figure 5a: Colony counts/ml from BAL performed at 24hrs in mice inoculated with 2.5 x 10 7 of
550
PAO1 and treated with 20l bacteriophage cocktail (containing 1.24 x 109 PFU) or 20l SM
551
buffer prophylactically, 48hrs prior to infection. If no colonies were visible to the naked eye, this
552
is reported as 0 CFU/ml; the theoretical limit of detection was 100 CFU/ml as 10l drops of
553
BALF were cultured.
554
Figure 5b: KC (median/range) from BAL performed at 24hrs in mice inoculated with 2.5 x 10 7 of
555
PAO1 and treated with 20l bacteriophage cocktail (containing 1.24 x 109 PFU) or SM buffer
556
prophylactically, 48hrs prior to infection.
26
557
Figure 6: Differential cell counts (median/range) from BAL performed at 24hrs in mice
558
inoculated with 2.5 x 107 of PAO1 and treated with 20l bacteriophage cocktail (containing 1.24
559
x 109 PFU) or SM buffer prophylactically, 48hrs prior to infection.
560
27